26577-57-1

Basic information

• Product Name: 4-(4-Morpholinyl)benzeneacetic acid
• Synonyms: 4-(4-Morpholinyl)benzeneacetic acid;2-[4-(morpholin-4-yl)phenyl]acetic acid
• CAS NO: 26577-57-1
• Molecular Formula: C₁₂H₁₅NO₃
• Molecular Weight: 221.2524
• Mol File: 26577-57-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Morpholinyl)benzeneacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Morpholinyl)benzeneacetic acid(26577-57-1)
• EPA Substance Registry System: 4-(4-Morpholinyl)benzeneacetic acid(26577-57-1)

Safety Data

• Hazardous Substances Data: 26577-57-1(Hazardous Substances Data)

Upstream product

• 39911-99-4 ethyl 4-(morpholin-4-yl)phenylacetate 
• 110-91-8 morpholine 
• 39910-98-0 4-morpholinoacetophenone 
• 14062-25-0 Ethyl 4-bromophenylacetate 

Downstream Products

• 1450907-82-0 C₂₁H₂₁N₃O 
• 1450907-83-1 C₂₅H₃₁NO₅ 
• 1450907-93-3 C₂₁H₃₃N₃O₅ 
• 111601-67-3 methyl 4-morpholinophenylacetate 
• 111601-71-9 4-morpholinophenylacetic acid N-oxide 
• 111601-69-5 picrate of methyl 4-morpholinophenylacetate N-oxide 
• 111601-70-8 hydrochloride of morpholinophenylacetic acid N-oxide 
• 1027325-14-9 N-[5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-hydroxy-phenyl]-2-(4-morpholin-4-yl-phenyl)-acetamide 

Relevant articles and documents

USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS

A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compo

Decarboxylative allylation of amino alkanoic acids and esters via dual catalysis

A combination of photoredox and palladium catalysis has been employed to facilitate the room temperature decarboxylative allylation of recalcitrant amino and phenylacetic allyl esters. This operationally simple process produces CO2as the only b

PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.